- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
December 17, 2020
This episode of Px Pulse explores an exciting new option for HIV prevention—long-acting injectable cabotegravir (CAB-LA). In 2020, early results from two trials—HPTN 083 and HPTN 084—showed CAB-LA was safe and highly effective at preventing HIV when compared to daily oral TDF/FTC (Truvada) in men who have sex with men (MSM), transgender (TG) women and cisgender women. Overall HIV incidence rates in the trials were remarkably low, demonstrating that both oral and injectable PrEP are safe and effective options.
Now what? What questions remain unanswered and what support is needed now to make the growing range of prevention options feasible choices for people who may want and need them?
In this episode, Raphael Landovitz and Sinead Delany-Moretlwe, lead investigators of the HPTN 083 and 084 trials, respectively, lay out the topline research findings and discuss how CAB-LA fits in with existing HIV prevention options.
And with an eye on translating research into implementation and impact, Definate Nhamo, a program manager from Pangaea Zimbabwe AIDS Trust (PZAT), and Jason Reed, a technical advisor with Jhpiego, outline priorities for the work ahead in policy making, programming and funding to get CAB-LA to those who need it, as part of an expanding toolbox for HIV prevention.
Listen
Highlights
- Lead researchers for HPTN 084 & 083 on the high efficacy of CAB-LA and remaining questions (12:11)
- What’s next for CAB-LA from an advocate and implementer perspective (11:01)
Transcript
Resources
- Dedicated webpage on long-acting injectable cabotegravir, AVAC
- An Advocates’ Primer on Long-Acting Injectable Cabotegravir for PrEP: Understanding the Initial Results of HPTN 083, AVAC
- HPTN 083 Final Results Presentation, HPTN at AIDS2020
- HPTN 084 Primary Study Results Webinar, HPTN webinar
- HPTN 084 FAQ, HPTN
- Biomedical Prevention Implementation Collaborative (BioPIC), AVAC